CJC12955mg,99%PurityHot-sellinginPhco ker
-ByPhcokercomCJC1295Structure
Authoritativesource：PubChem
WhatIsCJC-1295Peptide?
CJC-1295,alsoknownasDAC:GRF(DrugAffinityComplex:GrowthHormone-ReleasingFactor), isasyntheticpeptidederivativeofgrowthhormone-releasinghormone(GHRH).Therearetwo mainformsofCJC-1295availableonthemarket:CJC-1295withDACandCJC-1295withoutDAC (alsoknownasModifiedGRF1-29).
WhatisCJC-1295withDAC?
ThisformofCJC-1295includesDAC(DrugAffinityComplex),whichhelpstopreventdegradation ofthepeptideovertime,thusprolongingitsactivityCJC-1295withDACisasyntheticGHRH analoguecomposedof30aminoacids.Itstimulatesgrowthhormonesecretionandinsulin-like growthfactor(IGF-1)levels,leadingtoincreasedmusclemass,improvedbonedensity,andother benefitsassociatedwithgrowthhormone.ItisknownforprovidingsteadyincreasesinHGHand IGF-1levelswithoutaffectingprolactinlevels,whichcanleadtofatlossandincreasedprotein synthesis.
WhatisCJC-1295withoutDAC(ModifiedGRF1-29)?
ThisformofCJC-1295lackstheDACcomponentItisalsoasyntheticpeptidethatstimulates growthhormoneproductionWhileitdoesn'thavethesameprolongedactivityasCJC-1295with DAC,itisstilleffectiveinpromotinggrowthhormonesecretionItcanassistwithrapidbodyfat reduction,fasterrecoveryfromstrenuousactivity,andsubstantialmusclegain.Whenusedin combinationwithotherpeptideslikeIpamorelin,itcanproducesimilarincreasesingrowth hormonesecretionwithoutcertainsideeffectslikeincreasedappetiteandcortisollevels.
BothformsofCJC-1295havetheirbenefitsandapplicationsdependingonindividualneedsand preferencesCJC-1295withDACmaybepreferredforitslonger-lastingeffects,whileCJC-1295 withoutDACmaybechosenforitsrapidactionandpotentialsynergieswhencombinedwithother peptidesIt'sessentialtosourcethesepeptidesfromreputablemanufacturersorsellers,like Phcoker.comtoensurequalityandeffectiveness.
CJC-1295:GHRH&DAC
CJC-1295,asyntheticpeptidederivedfromgrowthhormone-releasinghormone(GHRH),offers enhancementsoveritsprecursorSermorelinbyextendingitshalf-life,thusprolongingitseffects.
GHRHisahormoneproducedinthehypothalamus,whichstimulatesthereleaseofgrowth hormone(GH)fromthepituitaryglandinapulsatilemannerThispulsatilereleasepatterniscrucial formaintainingnormalphysiologicallevelsofGHinthebody
Tofurtherenhancethehalf-lifeofCJC-1295,aDrugAffinityComplex(DAC)isaddedDACbinds toabloodproteincalledalbumin,effectivelyincreasingthepeptide'shalf-lifetoapproximately8 days.Thisprolongedhalf-lifereducesthefrequencyofinjectionsrequired,typicallytoonceor twiceaweek,comparedtoshorter-actingpeptideslikeSermorelin.Whiletheextendedhalf-lifeof CJC-1295withDACoffersconvenienceinadministration,maintainingconstantbloodlevelsofthe peptidecanleadtoasustainedstimulusforGHreleasefromthepituitaryglandHowever,this constantstimulationmaynotmimicthenaturalpulsatilepatternofGHsecretionseenwith endogenousGHRH
TheconstantstimulationprovidedbyCJC-1295withDACcanleadtoadecreaseintheamplitude ofGHpulses.ThisreducedpulseamplitudemayresultindecreasedGHtissuestimulationover time,potentiallyimpactingtheeffectivenessofthepeptideinpromotingmusclegrowth,fatloss, andotherdesiredeffects
Insummary,whileCJC-1295withDACofferstheconvenienceoflessfrequentdosingand prolongedeffects,itsconstantstimulationofGHreleasemaynotperfectlyreplicatethe physiologicalpulsatilepatternseenwithnaturalGHRHsecretion.Thisconsiderationshouldbe weighedagainstitsbenefitswhendecidingonitsusefortherapeuticorperformance-enhancing purposes.
ReferencedCitations
[1]TeichmanSL,NealeA,LawrenceB,GagnonC,CastaigneJP,FrohmanLAProlongedst imulationofgrowthhormone(GH)andinsulin-likegrowthfactorIsecretionbyCJC-1295, along-actinganalogofGH-releasinghormone,inhealthyadults.JClinEndocrinolMetab. 2006Mar;91(3):799-805.Epub2005Dec13
[2]Sackmann-SalaL,DingJ,FrohmanLA,KopchickJJActivationoftheGH/IGF-1axisb yCJC-1295,along-actingGHRHanalog,resultsinserumproteinprofilechangesinnormal adultsubjectsGrowthHormIGFRes2009Dec;19(6):471-7doi:101016/jghir20090300 1Epub2009Apr21
[3]Jumpupto:abcdefTeichmanSL,NealeA,LawrenceB,GagnonC,CastaigneJP,F rohmanLA(March2006).“Prolongedstimulationofgrowthhormone(GH)andinsulin-like growthfactorIsecretionbyCJC-1295,along-actinganalogofGH-releasinghormone,inh ealthyadults”TheJournalofClinicalEndocrinologyandMetabolism91(3):799–805doi: 101210/jc2005-1536PMID16352683
[4]JettéL,LégerR,ThibaudeauK,BenquetC,RobitailleM,PellerinI,etal.(July2005). “Humangrowthhormone-releasingfactor(hGRF)1-29-albuminbioconjugatesactivatetheGR Freceptorontheanteriorpituitaryinrats:identificationofCJC-1295asalong-lastingGR Fanalog”.Endocrinology.146(7):3052–8.doi:10.1210/en.2004-1286.PMID15817669
[5]Jumpupto:abcAlbaM,FintiniD,SagazioA,LawrenceB,CastaigneJP,FrohmanL A,SalvatoriR(December2006)Once-dailyadministrationofCJC-1295,along-actinggrow thhormone-releasinghormone(GHRH)analog,normalizesgrowthintheGHRHknockout mouse.AmericanJournalofPhysiology.EndocrinologyandMetabolism.291(6):E1290-4. doi:10.1152/ajpendo.00201.2006.PMID16822960
[6]IonescuM,FrohmanLA(December2006)“Pulsatilesecretionofgrowthhormone(GH) persistsduringcontinuousstimulationbyCJC-1295,along-actingGH-releasinghormoneana log”TheJournalofClinicalEndocrinologyandMetabolism91(12):4792–7doi:101210/j c2006-1702PMID17018654
[7]“CurrentResearchFindingsRegardingCJC-1295”.NeoScientific.2June2015.Archived
fromtheoriginalon7April2019.Retrieved3August2015.ThereasonwhyCJC1295pos sessestheabilitytolengthenthehalf-lifewithintheactiveagenthastodowiththescienti ficprocessknownasbioconjugationThistechnology,whichisrelativelynewinnature,is definedbyitsabilitytotakeareactivegroupandbondittoapeptide(AslamandDent) Thisattachmentcausesareactionwithanucleophilicunit;atypicallypartiallymoleculetha tisfoundwithinthebloodstreamofananimaltestsubject.Thisreactioninturncausesa morestablebondtooccur.Thisspecificpeptidehasanespeciallyhighattractiontoalbumi n,aglobularproteinthatissolubleinwater.Thisaffinityprohibitsnaturaldegradation,whi chinturnincreasesthepeptide’shalf-life(Hermanson)Additionally,clinicalresearchperfor medonanimaltestsubjectshasthusfarshownthattherehavebeennosignsofDPP-IVd egradationpresentwhenCJC-1295wasintroduced(Gonzalez,USPeptideArticles)
[8]HenningeJ,PepajM,HullsteinI,HemmersbachP(2010).“IdentificationofCJC-1295,a growth-hormone-releasingpeptide,inanunknownpharmaceuticalpreparation”.DrugTesting andAnalysis.2(11–12):647–50.doi:10.1002/dta.233.PMID21204297
[9]Alba,M,Fintini,D,Sagazio,A,Lawrence,B,Castaigne,JP,Frohman,LA,&Sal vatori,R(2006)Once-dailyadministrationofCJC-1295,along-actinggrowthhormone-relea singhormone(GHRH)analog,normalizesgrowthintheGHRHknockoutmouseAmericanJ ournalofPhysiology-EndocrinologyandMetabolism,291(6),E1290-E1294
[10]VanHout,M.C.,&Hearne,E.(2016).Netnographyoffemaleuseofthesyntheticgro wthhormoneCJC-1295:pulsesandpotions.SubstanceUse&Misuse,51(),73-84
[11]NationalCenterforBiotechnologyInformation“PubChemCompoundSummaryforCID 91976842,CJC1295WithoutDAC”PubChem
[12]TimmsM,GanioK,SteelR.”AmethodforconfirmingCJC-1295abuseinequineplas masamplesbyLC-MS/MS”DrugTestAnal.2019Aug;11(8):1248-1257.doi:10.1002/dta.259
9.Epub2019May8.PMID:30938069
[13]KwokWH,HoEN,LauMY,LeungGN,WongAS,WanTS”Dopingcontrolanalysis ofsevenbioactivepeptidesinhorseplasmabyliquidchromatography-massspectrometry”A nalBioanalChem2013Mar;405(8):2595-606doi:101007/s00216-012-6697-9Epub2013J an15.PMID:23318763
[14]MemdouhS,GavrilovićI,NgK,CowanD,AbbateV.”Advancesinthedetectionofgr owthhormonereleasinghormonesyntheticanalogs”DrugTestAnal2021Nov;13(11-12):18 71-1887doi:101002/dta3183Epub2021Nov7PMID:34665524
[15]PineauT,SchopferA,GrossriederL”Thestudyofdopingmarket:Howtoproduceintel ligencefromInternetforums”ForensicSciInt.2016Nov;268:103-115.doi:10.1016/j.forsciint. 2016.09.017.Epub2016Sep27.PMID:27710891